Introduction: YouTube™ is a widely accessible platform with unfiltered medical information. This study aimed to evaluate the educational value and reliability of YouTube™ videos on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced epithelial ovarian cancer treatment.Methods: YouTube™ videos were searched using the keywords “ovarian cancer”, “debulking surgery”, “hyperthermic”, and “HIPEC”. Patient Education Materials Assessment Tool for Audiovisual Content (PEMAT A/V) score, DISCERN, Misinformation Scale, and the Global Quality Scale (GQS) were employed to assess the clarity, quality, and reliability of the information presented.Results: Of the 150 YouTube™ videos screened, 71 were suitable for analysis and categorized by target audience (general public vs. healthcare workers). Most (57, 80.2%) were uploaded after the “Ov-HIPEC” trial (18 January 2018), with a trend toward more videos for healthcare workers (p= 0.07). Videos for the general public were shorter (p< 0.001) but received more views (p= 0.06) and likes (p= 0.09), though they were of lower quality. The DISCERN score averaged 50 (IQR: 35–60), with public-targeted videos being less informative (p< 0.001), a trend mirrored by the Misinformation Scale (p< 0.001) and GQS (p< 0.001). The PEMAT A/V scores showed 80% Understandability (IQR: 62–90) and 33% Actionability (IQR: 25–100), with no significant difference between groups (p= 0.15,p= 0.4).Conclusions: While YouTube™ provides useful information for healthcare professionals, it cannot be considered a reliable source for patients seeking information on HIPEC for ovarian cancer. Many videos contribute to misinformation by not properly explaining treatment indications, timing, adverse effects, multimodal approaches, or clinical trial findings.
引言：YouTube™是一个广泛可访问且包含未经筛选医学信息的平台。本研究旨在评估YouTube™上关于晚期上皮性卵巢癌治疗中腹腔热灌注化疗（HIPEC）视频的教育价值与可靠性。 方法：使用关键词"卵巢癌"、"肿瘤细胞减灭术"、"热灌注"和"HIPEC"检索YouTube™视频。采用视听内容患者教育材料评估工具（PEMAT A/V）评分、DISCERN量表、错误信息量表和全球质量量表（GQS）对视频信息的清晰度、质量及可靠性进行评估。 结果：在筛选的150个YouTube™视频中，71个符合分析标准，并按目标受众（普通公众与医护人员）分类。大多数视频（57个，80.2%）发布于"Ov-HIPEC"临床试验（2018年1月18日）之后，且呈现面向医护人员的视频数量增多趋势（p=0.07）。面向普通公众的视频时长较短（p<0.001），但获得更多观看量（p=0.06）和点赞数（p=0.09），尽管其质量较低。DISCERN评分中位数为50（四分位距：35-60），其中公众向视频信息量显著不足（p<0.001），这一趋势在错误信息量表（p<0.001）和GQS评分（p<0.001）中得到印证。PEMAT A/V评分显示可理解度为80%（四分位距：62-90），可执行度为33%（四分位距：25-100），组间无显著差异（p=0.15，p=0.4）。 结论：尽管YouTube™为医疗专业人员提供了有用信息，但对于寻求卵巢癌HIPEC治疗信息的患者而言，该平台并非可靠信息来源。许多视频因未恰当说明治疗适应症、时机、不良反应、多模式治疗方案或临床试验结果而助长了错误信息的传播。
肿瘤(癌症)患者之家